Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
about
Comparison of echinocandin antifungalsCombination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisIn vitro activity of caspofungin against Candida albicans biofilms.Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.Overview of vertebrate animal models of fungal infection.Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis.New methods to assess susceptibilities of Aspergillus isolates to caspofungin.Caspofungin: first approved agent in a new class of antifungals.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definitionEfficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulansPhase II dose escalation study of caspofungin for invasive Aspergillosis.New and emerging antifungal agents: impact on respiratory infections.Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.Antifungal pharmacokinetics and pharmacodynamicsElevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelDetermination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Caspofungin: an overview.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.The echinocandins.Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.Automated and manual methods of DNA extraction for Aspergillus fumigatus and Rhizopus oryzae analyzed by quantitative real-time PCRPopulation pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosisThe pharmacology and clinical use of caspofungin.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.
P2860
Q28273738-F2A9AB82-6FC3-4A30-B427-CFA54591D005Q28727508-C6CDDA79-4A59-4813-9DD9-9337039F38CEQ31114513-15A08C01-17CD-4498-B2AC-E2C081020C8FQ33366929-06656BC1-7149-4B1C-981F-3CA86B51254EQ33689767-D1D3520E-4A60-4A1A-885D-602463F764A5Q33757912-8D30B88B-D2C5-4E0B-B572-DF0FA38ADCC3Q34123805-C0F2BB7F-6238-42D7-9A66-83CF826D42A8Q34175500-28F65EA3-75B8-4717-B9D1-0968940CB9D0Q34228214-6809FC89-1985-4363-9CE2-69CCB03C45CCQ34510443-D237F0D1-3088-409A-B9CC-AC84AB1C7989Q34719835-5A74DC1B-37B8-43E6-B04A-75767C2732D9Q34952419-3BEF2A0F-8373-434F-9076-954B8F5F4388Q34956645-F36EE021-7DBC-47FF-8060-374B97F906B0Q35124726-BA3AB61C-5E9B-408E-886A-C873F5157745Q35185757-6AA25AF6-4156-4946-A660-DF08D4D7C37EQ35194409-A8C04DBA-2E0A-4C27-8016-0DA9C50AED49Q35215384-BCA8AD23-941F-4B1A-99A9-6C5ADAA81985Q35598439-C328260A-0597-457E-829F-939868CAABFDQ35627629-F6B50724-DEF7-4692-81AC-F9ED9F07F560Q35647724-A8B3B491-73B2-4CF3-B984-81BEE93D6AC9Q35663841-CDDF743F-A40B-4AB3-BA13-1508633D10D7Q35666505-10310EFE-E591-4B70-8E0F-D244E5B3DE17Q35666627-3C18819F-F5A1-42C4-A8D9-F9C395349A94Q35745822-11C5FB6D-63D0-42DF-AD33-1BF592202FA7Q35840760-7340D962-A498-4747-ADEF-E0E5E872056EQ36176371-A8723B4C-36F0-437E-A0FD-82717284B04EQ36278031-FEE927E3-D831-4EC9-97EA-863556F7C5FDQ36425025-D1B02293-7EC7-4BB3-8A93-45141CB41C88Q36441524-69FC7ECD-0D41-4579-9731-20601BE880FFQ36626518-C508A452-70D7-4C31-A989-1E22A4F19708Q36742397-F986BB35-B042-476D-BC8E-4F3E3B3EBD16Q36744831-B0722F8E-E70A-45F9-8E30-495283A65954Q36747468-82EF74C1-4641-4589-99DE-FEDE524E6569Q36757591-82C18E2D-56A6-48D7-B8EE-DD5AF9FEB7C3Q36788428-EDD20BCA-CF19-4C67-BBF9-8F390B83EF1CQ36932989-41C87AB1-866E-44E8-A0D4-D49FE7B4CF68Q36948094-51A9EE82-B384-4B59-ACA2-61F6B87FAC01Q36949553-A8A0FDF2-FF32-48B7-BBCC-386912BEDC75Q36983268-E99F4001-FA01-49C6-9ACB-AF46F1590FFDQ37121115-E61E83AF-9CC1-4165-BF8F-10B36E9B496D
P2860
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@ast
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@en
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@nl
type
label
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@ast
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@en
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@nl
prefLabel
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@ast
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@en
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@nl
P2093
P2860
P1476
Antifungal efficacy of caspofu ...... to galactomannan antigenemia.
@en
P2093
Andrea Francesconi
Andreas H Groll
John Bacher
Nilo A Avila
Robert L Schaufele
Ruta Petraitiene
Thomas J Walsh
Vidmantas Petraitis
P2860
P356
10.1128/AAC.46.1.12-23.2002
P407
P577
2002-01-01T00:00:00Z